INKT News and Press, MiNK Therapeutics Inc. From 03/18/22

AgenT-797 (Allo-iNKTs) +/- anti-PD-1 clinical trial underway in solid tumor cancers Benefit in severe COVID-19 ARDS shows 75% survival rate in patients treated with Allo-iNKTs AgenT-797 treatment with no lymphodepletion shows no cytokine release syndrome or neurotoxicity 202...

NEW YORK, March 03, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. , a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-...

MiNK Therapeutics (INKT +1.2%) began dosing in a phase 1 trial of AgenT-797 iNKT cell therapy alone and in combination with approved anti-PD-1 checkpoint inhibitors in patients with relapsed/refractory solid tumors. The company said pre-clinical data has shown the persistence, traff...

Clinical data show AgenT-797 can be dosed to 1 billion cells without lymphodepletion, with no evidence of cytokine release syndrome or neurotoxicity Clinical trials underway in solid tumor cancers, multiple myeloma, and viral ARDS NEW YORK, March 03, 2022 (GLOBE NEWSWIRE) --...

Botensilimab (Fc-enhanced) is the first anti-CTLA-4 antibody to demonstrate clinical responses across 9 cold, treatment-resistant cancers; Phase II studies planned in melanoma, MSS-colorectal, and pancreatic cancers AGEN1571, a novel program targeting tumor-associated macrophages, is ...

NEW YORK, Jan. 12, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics, a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated dis...

Mink Therapeutics (NASDAQ:INKT) plummeted more than 40% intraday Monday to a post-IPO low, falling on Wall Street’s apparent lack of enthusiasm for biotech names coupled with continued fallout from last week’s poorly received quarterly results. INKT sank as much as 41.1% intrada...

Listen on the go! A daily podcast of Wall Street Breakfast's Alpha Talks will be available this morning on Seeking Alpha, iTunes, Stitcher and Spotify. Stocks closed out the week with a decline, but managed to limit some damage with last-hour buying. The Nasdaq (COMP.IND) -1.9% took the brunt...

NEW YORK, Nov. 17, 2021 (GLOBE NEWSWIRE) -- MiNK Therapeutics, a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated dis...

No evidence of neurotoxicity or cytokine release syndrome Early signals of tumor biomarker suppression and disease stabilization beyond 6 months in relapsed/refractory multiple myeloma iNKTs demonstrated potent tumor killing in solid tumor models NEW YORK, Nov. 12, 2021 (G...